Background/Aims: It has been reported that children treated for acute lymphoblastic leukemia (ALL) in developed countries show an increased risk of overweight and obesity in adolescence and adulthood. However, the majority of patients who came to our observation in Brazil have low or normal body weight and only one of them was obese. Therefore, we have decided to assess some biochemical parameters possibly related to the intermediate metabolism and body composition in these patients. Methods: Two groups of subjects were studied: 27 survivors of childhood ALL (14.0 ± 4.2 years old; post-treatment interval 8.6 ± 3.9 years) (ALL group) and 17 healthy subjects (12.8 ± 4 years old) (control group) selected on the basis of their kinship with the patients. Results: 14/27 patients of the ALL group and 4/17 of the control group had leptin levels higher than the normal range for age and sex (p < 0.05). The leptin level was significantly higher in the ALL group (15.5 ± 1.8 ng/ml) than in the control group (10.7 ± 2 ng/ml) (p < 0.05). When adjusted by sex, BMI z-score, and age, the level of leptin in patients of the ALL group was 8.5 higher than in subjects of the control group (p = 0.006). Leptin/insulin correlation in the ALL group was 0.08 and in the control group it was +0.585 (p < 0.05). Conclusion: The data indicate the presence of alterations in the homeostatic regulatory mechanisms controlling body weight in Brazilian patients treated for ALL in childhood, still, it did not lead to obesity in the absence of favorable environmental conditions.

1.
Argüelles B, Barrios V, Buño M, Madero L, Argente J: Anthropometric parameters and their relationship to serum growth hormone-binding protein and leptin levels in children with acute lymphoblastic leukaemia: a prospective study. Eur J Endocrinol 2000;143:243–250.
2.
Reilly JJ, Kelly A, Ness P, Dorosty AR, Wallace WHB, Gibson BES, Emmett PM, ALSPAC Study Team: Premature adiposity rebound in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 2001;86:2775–2778.
3.
Odame I, Reilly JJ, Gibson BES, Donaldson MDC: Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1994;71:147–149.
4.
Zee P, Chen CH: Prevalence of obesity in children after therapy for acute lymphoblastic leukaemia. Am J Pediatr Hematol Oncol 1986;8:294–299.
5.
Schell MJ, Ochs JJ, Schrock EA, Carter M: A method of predicting adult height and obesity in long term survivors of childhood acute lymphoblastic leukaemia. J Clin Oncol 1992;10:128–133.
6.
Davies HA, Didcock E, Didi M, Ogilvy- Stuart A, Wales JKH, Shalet SM: Growth, puberty and obesity after treatement for leukaemia. Acta Paediatr 1995;411(Suppl):45–50.
7.
Mayer EI, Reuter M, Dopfer RE, Ranke MB: Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood. Horm Res 2000;53:193–199.
8.
Birkebaek NH, Clausen N: Height and weight pattern up to 20 years after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1998;79:161–164.
9.
Didi M, Didcock E, Davies HA, Ogilvy-Stuart AL, Wales JKH, Shalet SM: High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia during childhood. J Pediatr 1995;127:63–67.
10.
Brennan BMD, Rahim A, Blum WF, Adams JA, Eden OB, Shalet SM: Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin Endocrinol 1999;50:163–169.
11.
Nysom K, Holm K, Michaelsen KF, Hertz H, Muller J, Molgaard C: Degree of fatness after treatment for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 1999;84:4591–4596.
12.
Büllow B, Link K, Ahren B, Nilsson A-S, Erfurth EM: Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol 2004;61:683–691.
13.
Craig F, Leiper AD, Stanhope R, Brain C, Meller ST, Nussey SS: Sexually dimorphic and radiation dose dependent effect of cranial irradiation on body mass index. Arch Dis Child 1999;81:500–504.
14.
Oeffinger KC, Mertens AC, Sklar CA, Yasui Y, Fears T, Stovall M, Vik TA, Inskip PD, Robison LL: Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. J Clin Oncol 2003;21:1359–1365.
15.
Groot-Loonen JJ, Otten BJ, van’t Hof MA, Lippens RJ, Stoelinga GB: Influence of treatment modalities on body weight in acute lymphoblastic leukemia. Med Pediatr Oncol 1996;27:92–97.
16.
Birkebaek NH, Fisker S, Clausen N, Tuovimen V, Sindet-Pedersen S, Christiansen JS: Growth and endocrinological disorders up to 21 years after treatment for acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 1998;30:351–356.
17.
Warner JT, Bell W, Webb DK, Gregory JW: Relationship between cardiopulmonary response to exercise and adiposity in survivors of childhood malignancy. Arch Dis Child 1997;76:298–303.
18.
Sklar CA, Mertens AC, Walter A, Mitchell D, Nesbit ME, O’Leary M, Hutchinson R, Meadows AT, Robison LL: Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol 2000;35:91–95.
19.
Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, Sklar CA, Stovall M, Yasui Y, Robison LL: Genetic variations in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2004;22:3558–3562.
20.
Van Dongen-Melman JE, Hokken-Koelega AC, Hahlen K, De Groot A, Tromp CG, Egeler RM: Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 1995;38:86–90.
21.
Stallings VA, Vaisman N, Chan HSL, Weitzman SS, Clarke R, Pencharz PB: Energy metabolism in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Res 1989;26:154–157.
22.
Ahmed SF, Wallace WH, Kelnar CJ: An anthropometric study of children during intensive chemotherapy for acute lymphoblastic leukaemia. Horm Res 1997;48:178–183.
23.
Sainsbury CPQ, Newcombe RG, Hughes IA: Weight gain and height velocity during prolonged first remission from acute lymphoblastic leukaemia. Arch Dis Child 1985;60:832–836.
24.
Calzolari A, Baronci C, Biondi G: Evaluation of a group of leukaemic children ‘off therapy’ towards their inclusion in physical activities. Int J Sports Cardiol 1985;2:108–115.
25.
Bond SA, Han AM, Wootton SA, Kohler JA: Energy intake and basal metabolic rate during maintenance chemotherapy. Arch Dis Child 1992;67:229–232.
26.
Talvensaari KK, Lanning M, Tapanainen P, Knip M: Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 1996;81:3051–3055.
27.
Considine RV, Sinha MK, Helman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292–295.
28.
Casanueva FF, Dieguez C: Neuroendocrine regulation and action of leptin. Front Neuroendocrinol 1999;20:317–363.
29.
Magni P, Motta M, Martini L: Leptin: a possible link between food intake, energy expenditure, and reproductive function. Regul Pept 2000;92:51–56.
30.
Link K, Moell C, Garwicz S, Cavallin-Stahl E, Bjork J, Thilen U, Ahren B, Erfurth EM: Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 2004;89:5003–5012.
31.
Davies JH, Evans BA, Jones E, Evans WD, Jenney ME, Gregory JW: Osteopenia, excess adiposity and hyperleptinaemia during 2 years of treatment for childhood acute lymphoblastic leukaemia without cranial irradiation. Clin Endocrinol (Oxf) 2004;60:358–365.
32.
Marques RM, Marcondes E, Berquó E, Prani R, Yunes J: Crescimento e desenvolvimento pubertário em crianças e adolescentes brasileiros. II. Altura e Peso. São Paulo, Editora Brasileira de Ciências, 1982.
33.
Crist WM, Smithson WA: The leukemias; in Behrman RE, Kliegman RM, Jenson HB (eds): Nelson Textbook of Pediatrics, ed 16. Philadelphia, Saunders, 2000, pp 1694–1698.
34.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240–1243.
35.
Reilly JJ, Ventham JC, Newell J, Aitchison T, Wallace WH, Gibson BE: Risk factors for excess weight gain in children treated for acute lymphoblastic leukemia. Int J Obs Relat Metab Disord 2000;24:1537–1541.
36.
Bouchard C, Perusse L: Genetics of obesity. Annu Rev Nutr 1993;3:337–354.
37.
Pratley RE: Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: lessons learned from the Pima Indians. Proc Nutr Soc 1998;57:175–181.
38.
O´Dea K, White N, Sinclair A: An investigation of nutrition-related risk factors in an isolated Aboriginal community in northern Australia: advantages of a traditionally-orientated life style. Med J Aust 1988;148:177–180.
39.
O’Dea K: Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle. Diabetes 1983;33:596–603.
40.
Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, Xiong X, Wu S, Merchant TE: Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 2003;88:611–616.
41.
Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, Rubin P: Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993;328:87–94.
42.
Motta LACR, Martinelli C, Motta LDC, Abrahão AL, Farage Filho M, Gagliardi ART: Efeitos tardios na função hipotálamo-hipófise após tratamento de tumores parasselares. Arq Neuro-Psiquiatr 1991;49:299–306.
43.
Elimam A, Lindgren AC, Norgren S, Kamel A, Skwirut C, Bang P, Marcus C: Growth hormone treatment downregulates serum leptin levels in children independent of changes in body mass index. Hormone Res 1999;52:66–72.
44.
Niswender KD, Baskin DG, Schwartz MW: Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab 2004;15:362–369.
45.
Lustig RH, Rose SR, Burghen GA, Velasquez-Myeyer P, Broome DC, Smith K, Li H, Hudson MM, Heideman RL, Kun LE: Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by somatostatin agonist. J Pediatr 1999;135:142–144.
46.
Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW: Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000;49:1525–1533.
47.
Carantoni M, Abbasi F, Azhar S, Chen Y-D, Klebanov M, Wang P-W, Wamerdam F, Reaven GM: Plasma leptin concentrations do not appear to decrease insulin-mediated glucose disposal or glucose-stimulated insulin secretion in women with normal glucose tolerance. Diabetes 1998;47:244–247.
48.
Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R, Mudaliar SR, Olefsky J, Caro JF: Acute and chronic effects of insulin on leptin production in humans. Diabetes 1996;45:699–701.
49.
Bates SH, Meyers MG: The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 2003;14:447–452.
50.
Hirschler V, Aranda C, Calcagno Mde L, Maccalini G, Jadzinsky M: Can waist circumference identify children with the metabolic syndrome? Arch Pediatr Adolesc Med 2005;159:740–744.
51.
Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460–468.
52.
Lee S, Bacha F, Arslanian SA: Waist circumference, blood pressure, and lipid components of the metabolic syndrome. J Pediatr 2006;149:809–816.
53.
Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J: The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295–300.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.